News Novartis says novel drug could counter malaria resistance Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3.
News FDA unveils swift route to market for personalised drugs FDA reveals a regulatory pathway for personalised therapies based on 'plausible mechanism', drawing on the bespoke gene-editing treatment of Baby KJ.
News Change at the top of Recursion as co-founder leaves CEO role After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.
News Alkermes breaks new ground in narcolepsy with orexin drug Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.
News Bayer beats expectations with tougher times looming Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead.
News AI features in UK plan to reduce animal testing The UK government has set out an ambitious plan to phase out animal testing in scientific studies within five years.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.